Effect of bradykinin on nitric oxide production, urea synthesis and viability of rat hepatocyte cultures by unknown
BioMed CentralBMC Physiology
ssOpen AcceResearch article
Effect of bradykinin on nitric oxide production, urea synthesis and 
viability of rat hepatocyte cultures
Settimio Sesti, Guglielmo Martino*, Sergio Mazzulla and Rosa Chimenti
Address: Department of Cell Biology, University of Calabria, Italy
Email: Settimio Sesti - sesti@unical.it; Guglielmo Martino* - martino@unical.it; Sergio Mazzulla - mazzulla@unical.it; 
Rosa Chimenti - chimenti@unical.it
* Corresponding author    
Abstract
Background: It is well known that cytotoxic factors, such as lipopolysaccharides, derange
nitrogen metabolism in hepatocytes and nitric oxide (NO) is involved among the other factors
regulating this metabolic pathway. Hepatocytes have been shown to express large levels of NO
following exposure to endotoxins, such as bacterial lipopolysaccharide and/or cytokines, such as
tumour necrosis factor-α (TNFα), interleukin-1. The control role of arginine in both urea and NO
biosynthesis is well known, when NO is synthesized from arginine, by the NOS reaction, citrulline
is produced. Thus, the urea cycle is bypassed by the NOS reaction. Many authors demonstrated in
other cellular types, like cardiomyocytes, that bradykinin caused the increase in reactive oxygen
species (ROS) generation. The simultaneous increase of NO and ROS levels could cause
peroxynitrite synthesis, inducing damage and reducing cell viability. The aim of this research is to
study the effect of bradykinin, a proinflammatory mediator, on cell viability and on urea production
in cultures of rat hepatocytes.
Results: Hepatocytes were treated with bradykinin, that stimulates nitric oxide synthase (NOS).
NO release was determined using 4,5 diaminofluorescein diacetate (DAF-2DA), as fluorescent
indicator of NO. Addition of the NOS inhibitor, Ng-nitro-L-arginine methyl ester (L-NAME), to the
culture medium inhibited the increase of NO production. Exposure of hepatocytes to bradykinin
0,1 mM for 2 hours resulted in a significant decrease of urea synthesis. Cell viability, instead,
showed a significant decrease 24 hours after the end of bradykinin treatment as determined by 3-
(4,5-dimethyl-2-thiazolyl)-2,5diphenyl-2H-tetrazolium (MTT) assay. L-NAME addition recovered
urea production and cell viability at control values.
Conclusion: The findings suggest that the cell toxicity, after bradykinin treatment, effectively
depends upon exposure to increased NO levels and the effects are prevented by L-NAME. The
results show also that the increased NO synthesis induces a reduced urea production, that is
another index of cell damage.
Background
It is well known that cytotoxic factors, such as lipopolysac-
charides, derange nitrogen metabolism in hepatocytes
and nitric oxide (NO) is involved among the other factors
regulating this metabolic pathway [1]. NO is a free radical
that is involved in many cellular events. In the biological
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an oxidation intermediate, therefore is both an oxidant
and a reducing agent of metabolic products. Its biosynthe-
sis is mainly performed by converting L-arginine to L-cit-
rulline. L-arginine analogues, such as Ng-nitro-L-arginine
methyl ester (L-NAME), act as false substrates and are
selective inhibitors of NO synthesis. NO synthase (NOS)
is either a constitutive or inducible enzyme. The endothe-
lial isoform (e-NOS) and the neuronal isoform (n-NOS)
are constitutive. The inducible form of the enzyme (i-
NOS), has the main property to be not regulated by intra-
cellular calcium concentration and Ca2+-calmodulin com-
plex, unlike the constitutive form [2]. It is known that
iNOS is expressed by many cell types including macro-
phages, smooth muscle cells and hepatocytes [3]. Hepato-
cytes have been shown to express large levels of NO
following exposure to endotoxins, such as bacterial
lipopolysaccharide and/or cytokines, such as tumour
necrosis factor-α (TNFα), interleukin-1 [4,5]. NO may
posses both cytoprotective and cytotoxic properties,
depending on the amount and the isoform of NOS by
which it is produced [6]. NO generally mediates beneficial
responses, but becomes deleterious when coexistence
with enhanced superoxide formation leads to the synthe-
sis of peroxynitrite, a potent oxidant and nitrating agent
[7]. According to this hypothesis, authors studied the
effect of bradykinin, a proinflammatory mediator kinin,
on cell viability and on urea production in cultures of rat
hepatocytes. Kinins exert numerous physiological and
pathological actions; they partecipate in vascular and cel-
lular events that accompany the inflammatory processes.
In pathological states, kinins are thought to be implicated
in inflammatory diseases and in haemorrhagic and endo-
toxic shock [8]. To demonstrate the decrease of cell viabil-
ity and urea production by bradykinin, the authors
studied its effects on NO production. The measurements
of NO release from hepatocytes were investigated by using
a NO-specific fluorescence indicator, 4,5 diaminofluores-
cein diacetate (DAF-2DA) [9].
Results
Effect of bradykinin treatment on NO production
The amounts of released NO were measured using DAF-
2DA, that specifically reacts with the oxidized form of NO,
producing the fluorescent triazolofluorescein [9]. NO
determination was performed after 2 hours of incubation
in the presence of bradykinin (0.01 mM and 0.1 mM). As
shown in figure 1 the treatment with 0.01 mM bradykinin
did not produce NO increase compared to control, but 0.1
mM bradykinin increased significantly the NO release. In
contrast no appreciable NO release was observed during
the same period in hepatocytes cultured with 0.1 mM
bradykinin and 1.68 mM L-NAME.
Effect of bradykinin treatment on urea production
To evaluate urea synthesis after bradykinin treatment, the
hepatocytes were treated with 1 mM NH4Cl for 2 h. Figure
2 shows that only the treatment with 0.1 mM bradykinin
significantly decreased urea production and that the treat-
ment with 0.1 mM bradykinin and 1.68 mM L-NAME did
not produce a significant urea level decrease in compari-
son to control.
Effect of bradykinin treatment on cell viability
To determine the effects of bradykinin on cell viability,
the hepatocytes were exposed to bradykinin (either 0.01
mM or 0.1 mM) for an incubation time of 2 hours. In one
experimental series, the cell viability was determined by
MTT test after 2 hours of incubation. In a second one, cul-
ture medium containing bradykinin was removed and
replaced with the same fresh medium at 2 hours after the
addition of bradykinin, and then cell viability was meas-
ured 24 hours after the end of bradykinin treatment. The
MTT test after 2 hours of incubation does not indicate any
significant viability difference in treated hepatocyte cul-
tures in comparison to control (figure 3A). By MTT test
after 24 h (figure 3B), a significant lowering of viability is
observed in bradykinin 0.1 mM treated hepatocytes in
comparison to control. The decrease was significantly
reduced by the simultaneous treatment with L-NAME
1.68 mM even if always significantly lower than in con-
trol. Cell viability was validated by Trypan blue exclusion
test (Table 1).
Discussion
The role of NO as mediator of hepatic injury after endo-
toxic shock remains controversial [16]. Increased NO pro-
duction in response to cytokines has been demonstrated
in cultured hepatocytes [17]. Laskin et al. [18] demon-
strated that the induction of acute endotoxemia, caused
an increase in NO production in the liver. This was asso-
ciated with expression of inducible nitric oxide synthase
(iNOS) messenger m-RNA in hepatocytes. Also our data
showed an increase of NO production after 2 hours treat-
ment of culture with 0.1 mM bradykinin in an arginine
supplemented medium, as substrate for the synthesis of
NO. The simultaneous treatment with L-NAME, a known
inhibitor of NOS, blocked the increase of NO production.
In this work we analyzed the urea synthesis after bradyki-
nin treatment. Urea synthesis was decreased after 2 hours
treatment with bradykinin 0.1 mM and the simultaneous
treatment with L-NAME leaves urea biosynthesis unal-
tered. These data can be attributed to the control role of
arginine in both urea and NO biosynthesis. When NO is
synthesized from arginine, by the NOS reaction, cytrul-
line, an intermediate of urea cycle, is produced. Thus, the
urea cycle is bypassed by the NOS reaction [1]. Whether
NO exerts cytotoxic or cytoprotective action remains
unclear [6]. We also found a significant decrease ofPage 2 of 7
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kinin treatment. The simultaneous treatment of hepato-
cytes with L-NAME improves cell viability even if control
levels are not restored. The data show that the increased
NO production plays a role in liver damage induction,
that follows the proinflammatory mediator treatment.
The hepatocellular injury attributed to NO may be due
either to its direct cytotoxicity or its reaction with superox-
ide to produce the toxic nitrogen metabolite peroxynitrite
[19]. Oldenburg et al. [20], demonstrated in other cell
types, like cardiomyocytes, that bradykinin caused the
increase in reactive oxygen species (ROS) generation. At
last, our results show that the increased NO synthesis
induces a reduced urea production, that is an index of cell
Determination of NO release after treatment of hepatocytes with bradykininFigu e 1
Determination of NO release after treatment of hepatocytes with bradykinin. Fluorescence intensity was measured after 2 h 
incubation: with 10 µM DAF-2DA in basal conditions (white column, reference), in presence of 0.01 mM bradykinin (hatched 
column), in presence of 0.1 mM bradykinin (crosshatched column) and in presence of 0.1 mM bradykinin with 1.68 mM L-
NAME (black column). The excitation wavelength was 495 nm and the emission wavelength was 515 nm. Values, expressed as 
a percentage of control values, are the means ± S.E.M. (bars) of four independent experiments.  p < 0,05 compared with 
control
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with L-NAME decreases NO levels and sustains overall
biosynthesis activities and cell viability.
Conclusions
In summary, we conclude that 0.1 mM bradykinin treat-
ment induces an increase of NO levels and reduction of
urea synthesis in the hepatocytes. This increased NO pro-
duction mediates, after 24 hours, cell toxicity as shown by
MTT test. In contrast, the administration of the NOS
inhibitor L-NAME protects against cell damage and
increases urea levels, suggesting that NO plays a key role
in the bradykinin-induced liver damage.
Methods
Materials
Unless otherwise specified, all chemicals were obtained
from Sigma (St. Louis, MO, USA).
Determination of urea production after treatment of hepatocytes with bradykininFigu e 2
Determination of urea production after treatment of hepatocytes with bradykinin. Urea production was spectrophotometri-
cally determined at 600 nm after 2 h incubation with 1 mM NH4Cl in basal conditions (white column), in presence of 0.01 mM 
bradykinin (hatched column), in presence of 0.1 mM bradykinin (crosshatched column) and in presence of 0.1 mM bradykinin 
with 1.68 mM L-NAME (black column). Values, expressed as ng urea per cell per hour, are the means ± S.E.M. (bars) of four 
independent experiments.  p < 0,05 compared with control
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Determination of cell viability in hepatocytes treated with bradykinin. The cell viability was spectrophotometrically determined 
at 570 nm by MTT assay in hepatocytes incubated in basal conditions (white column), in presence of 0.01 mM bradykinin 
(hatched column), in presence of 0.1 mM bradykinin (crosshatched column) and in presence of 0.1 mM bradykinin with 1.68 
mM L-NAME (black column) for 2 h period. (A) Cell viability determined immediately after. (B) Cell viability determined after 
an additional 24 h incubation period in incomplete medium Results are expressed as a percentage of control. Values are the 
means ± S.E.M. (bars) of four independent experiments.  p < 0,05 compared with control.  p < 0,05 compared with control and 
0.1 mM bradykinin treated cells
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Hepatocytes were isolated from male rats, Wistar strain,
(180 to 200 gbw), by a modification of the method of Seg-
len [10]. All procedures on the animals were performed
according to the CEE directive n. 86/609 on animal exper-
imentation. Rats were anesthetized with diethylether, the
pre-perfusion of the liver in situ was performed at a rate of
20–30 ml/min with Ca2+-free Hanks balanced salt solu-
tion. The liver was then excised and the digestion was car-
ried out by adding 0.05% (w/v) collagenase (type IV) in
Hanks balanced salt solution supplemented with
CaCl2·H2O (0.0186 g/L) at a flux rate of 40 ml/min. At
this point liver was transferred to a square plate contain-
ing 100 ml of RPMI 1640 medium supplemented with
200 mM L-glutamine, 20 ml/L essential amino acid solu-
tion and 10 ml/L non-essential amino acid solution, 1%
antibiotic antimycotic stabilized solution and 100 µM L-
arginine (incomplete medium). The cells were dispersed
by gentle distruption with a stainless steel comb. After fil-
tration through 200 µm Nytal mesh, parenchymal cells
(hepatocytes) were separated from nonparenchymal cells
(endothelial cells, Kupffer cells and stellate cells) by cen-
trifugation at 50 g in Eppendorf Centrifuge 5810R at 4°C
for 2 minutes and then washed twice in washing buffer
[11]. Then the cells were resuspended in the same
medium and filtered through 63 µm Nytal mesh. The via-
bility of the cells was more than 80%, as estimated by
trypan blue dye exclusion test [12]. After cell counting the
cells were diluited at a concentration of 5 × 105 cells/ml
with incomplete medium supplemented with 2% fetal
calf serum, 0.1 U/ml insulin and 10-6 M dexamethasone
(complete medium). The hepatocytes were then plated in
24 well-plates coated with rat tail collagen at the final cell
density of 2.5 × 105 cells per well and incubated at 37°C
in an humidified atmosphere of 5% CO2 and 95% air.
After 6 hours incubation, the medium was changed and
replaced with incomplete medium to remove dead cells.
To verify the isolation method efficiency, the acid fosfa-
tase activity per mg of proteins was evaluated. According
to literature data, the specific activity of acid fosfatase in
nonparenchimal cells is 1,7 folds the same activity in
parenchimal cells [13].
Treatment
After 24 hours of culture the hepatocytes were exposed
either to bradykinin (0.01 mM and 0.1 mM) or bradyki-
nin 0.1 mM supplemented with L-NAME 1.68 mM [14].
Determination of NO from hepatocytes
DAF-2DA (Alexis Biochemicals, Lausen, Switzerland) was
dissolved in DMSO (1 mg/0.45 ml) and diluted to 10 µM
in phosphate buffer (0.1 M, pH 7.4). Then the cells were
either incubated in phosphate buffer containing 10 µM
DAF-2DA, bradykinin (0.01 mM and 0.1 mM) and brady-
kinin 0.1 mM supplemented with L-NAME 1.68 mM.
After 2 hours of incubation in this reaction mixture, the
fluorescence from the reaction of DAF-2DA with NO
released from hepatocytes was measured with Perkin-
Elmer MPF-44B Spectrofluorimeter calibrated for excita-
tion at 495 nm and emission at 515 nm. Results were
expressed as a percentage of the fluorescence of the sam-
ples in comparison to control.
Determination of urea synthesis
To determine the effects of bradykinin on urea produc-
tion, cells were treated either with bradykinin (0.01 mM
and 0.1 mM) and cotreated with bradykinin 0.1 mM and
L-NAME 1.68 mM. At the same media 1 mM NH4Cl was
added. After 2 hours urea levels in the media were meas-
ured by spectrophotometric method using Urea Color 2
Kit (Sclavo Diagnostics, Siena, Italia) measuring absorb-
ance at 600 nm and blank sample with the same NH4Cl
final concentration was used. Urea synthesis was calcu-
lated as ng urea per cell per hour.
Table 1: Effect of bradykinin treatment on cell viability
Treatment: 2 h+Brad (Viability %) Treatment: 2 h+Brad + 24 h-Brad (Viability %)
Control 100 ± 10 100 ± 6
0.01 mM Bradykinin 98 ± 12 104 ± 10
0.1 mM Bradykinin 104 ± 8 50 ± 11*
0.1 mM Bradykinin + 1.68 mM L-NAME 102 ± 10 79 ± 7**
Hepatocytes were isolated and cultured in presence and in absence of bradykinin (either 0.01 mM or 0.1 mM) and cotreated with bradykinin 0.1 
mM and L-NAME 1.68 mM for a 2 h period. Cell viability was determined by Trypan blue exclusion test either immediately after 2 h or after 
additional 24 h incubation period in incomplete medium. Results are expressed as a percentage of control. Values are expressed as mean ± S.E.M., 
n = 4.
*Statistically significant differences (p < 0,05) from control levels as determined by Student's t-test.
** Statistically significant differences (p < 0,05) from control levels and from 0.1 mM bradykinin treated cells as determined by Student's t-test.Page 6 of 7
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Determination of cell viability
Cell viability was determined by MTT test method [15]
and confirmed by Trypan blue exclusion test [12]. MTT (5
mg/ml) was dissolved in RPMI-1640 without phenol red.
The solution is filtered through a 0.2 µm filter and stored
at 2–8°C for frequent use. To determine the effects of
bradykinin on cell viability, cells were either treated with
bradykinin (0.01 mM and 0.1 mM) and cotreated with
bradykinin 0.1 mM and L-NAME 1.68 mM for a 2 h
period. After that cells were used either immediately or
after an additional 24 h incubation period in incomplete
medium. For the determination of cell viability, the
medium has been discarded and MTT solution was added
and incubated for 3 hours. At the end of the incubation
period the MTT solution was removed and the cells and
dye cristals were dissolved by adding dimethylsulfoxide
(DMSO). Absorbance was measured at 570 nm in a Shi-
madzu UV-2100 Spectrophotometer and the results were
expressed as a percentage of the absorbance of the samples
in comparison to control.
Statistical analysis
At least four independent determinations of each param-
eter were compared to control using Student's T-test. Dif-
ferences were considered significant when p < 0.05 was
obtained.
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